Story

Check Point Software Stock Slides on Analyst Downgrade Over Churn, Weak Pipeline

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20262 min read
Check Point Software Stock Slides on Analyst Downgrade Over Churn, Weak Pipeline

Summary

Shares of cybersecurity firm Check Point Software fell sharply after Raymond James downgraded the stock, citing deteriorating channel checks, a bleak sales pipeline, and new, concerning instances of customer churn.

Text size
Background

Shares of Check Point Software Technologies (NASDAQ: CHKP) dropped nearly 5.0% in pre-open trading on Monday following a key analyst downgrade. The sell-off was triggered after Raymond James lowered its rating on the cybersecurity company to Market Perform from a previous Outperform rating, citing worsening business fundamentals.

Analysts Flag Execution Risks

In a note to clients, Raymond James analyst Adam Tindle pointed to deteriorating "field intelligence" as the basis for the downgrade. The firm's channel checks revealed several growing concerns for Check Point, including:

  • A broad-based decline in bookings.
  • A "bleak" deal pipeline for the second half of the year.
  • New and concerning instances of customer churn.
  • Internal personnel changes that have created confusion among channel partners, hampering renewal execution.

Raymond James also highlighted a "meaningful product gap" for Check Point in the endpoint security market, an area of growing importance in an AI-driven environment. Adding to the pressure, a separate negative note from Cleveland Research raised concerns about the company's limited upsell opportunities and challenges across its product portfolio.

A Challenging Backdrop

Sample IUX Markets – In-articleAd

The negative analyst commentary comes at a sensitive time for Check Point investors. The stock had already fallen roughly 27% over the six months prior to Monday's trading, with 33 analysts having revised their earnings estimates downward in recent months.

The company's first-quarter 2026 results had previously disappointed the market, with product revenue declining 3% year-over-year. Check Point attributed that weakness to go-to-market disruptions from internal management changes, making investors wary of further execution issues ahead of its second-quarter earnings report scheduled for July 30.

Market Reaction

The decline in Check Point's stock is a company-specific event, standing in contrast to a positive tone in the broader market, with the S&P 500 and Nasdaq both trading higher. Key cybersecurity peers such as Fortinet and Palo Alto Networks were not cited as facing similar pressures, further isolating the weakness to Check Point.

With the stock already trading well below its 52-week high of $225.23, the convergence of a formal downgrade and corroborating negative research appears to have prompted investors to reduce exposure ahead of the upcoming earnings release.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST